INAB vs INKT

IN8bio, Inc. vs MiNK Therapeutics, Inc. — Valuation Comparison 2026

INAB

Biotechnology
IN8bio, Inc.
Quality
3.2
out of 10
Value Trap
36
LOW
Price
$1.80
Last close
Models
7/13
Active
VS

INKT

Biotechnology
MiNK Therapeutics, Inc.
Quality
4.0
out of 10
Value Trap
18
SAFE
Price
$12.20
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType INAB Fair ValueINAB Upside INKT Fair ValueINKT Upside
Bayesian DCF Intrinsic $1.60 -10.9% $4.31 -64.7%
Earnings Power Value Intrinsic $3.25 -72.0%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.60 +99.9% $4.56 -62.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for INAB vs INKT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INAB vs INKT — Which Stock Is More Undervalued?

INKT scores higher with a 4.0/10 quality rating vs INAB's 3.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing IN8bio, Inc. (INAB) and MiNK Therapeutics, Inc. (INKT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INAB currently trades at $1.80 with a QOC of 3.2/10, while INKT trades at $12.20 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).